HITI · High Tide Inc.

High Tide's Exhibit 99.1 press release highlights a milestone for its 51%-owned subsidiary Remexian Pharma GmbH, which achieved a record 7.6 tonnes of medical cannabis distributed into the German market during the fiscal second quarter ended April 30, 2026. This represents a 21% increase from the prior quarter and 49% growth year-over-year, underscoring the scaling of Remexian's distribution platform in Europe's largest medical cannabis market. CEO Raj Grover attributes this success to combining Remexian's leading German infrastructure with High Tide's procurement expertise from over $2.2 billion in Canadian cannabis sales. Remexian, licensed to import from 19 countries including Canada, commands over 10% of Germany's import tonnage share. Contextually, Germany's 2025 imports surged to 201.1 tonnes from 72.9 tonnes the prior year, with over 93 tonnes sourced from Canada per BfArM data. Management views this as validation of a repeatable model for European expansion, subject to regulations, while aiming to gain further share in Germany. These preliminary, unaudited figures await confirmation in full Q2 financials, including revenue and adjusted EBITDA, slated for June 2026. Investors should note the forward-looking elements on growth and expansion carry risks outlined in the release.